Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2024.10.07

Sai Life Sciences' eco-friendly campus with green landscaping and modern architecture at sunset, featured in a blog post about the company's 2024 Sustainability Report

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here.

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “Overall, it has been a year of climate action for Sai Life Sciences. Today, renewable energy constitutes over 50% of our energy consumption at an organisational level. During the year, we also added newer decarbonisation levers to our programme, which have made significant contributions to reducing GHG emissions. This has been possible through sustained efforts, year on year, to strengthen our sustainability ecosystem and continually raise the bar.”


Last year, Sai Life Sciences renewed its Sustainable Development Goals (SDGs), outlining a clear roadmap to meet environmental, social, and governance (ESG) targets by March 31, 2027. The company has made notable progress in key areas, including reducing greenhouse gas emissions, sourcing energy from renewable sources and lowering specific water consumption. It has also exceeded its goal of providing education and livelihoods to 8,000 individuals from underprivileged communities through corporate social responsibility (CSR) programs. Women employees constitute 14.3% of the workforce, with numbers increasing year-on-year.

In recent years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda. Some of the notable highlights:

  1. Joined the Science Based Targets initiative (SBTi), committing to fight climate change with Science.
  2. Became the first India-headquartered company to join the Pharmaceutical Supply Chain Initiative (PSCI) membership.
  3. Strengthened culture of Health & Safety, along with making significant investments in upgrading infrastructure and systems.
  4. Won several prestigious awards for excellence in Environment, Health and Safety (EHS) practices and energy management.

[1] Among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR over FY22-24.

Share article

More News

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more

2025.08.13

Peptide Science & Beyond: Masterclass & Fireside Chat with IISc Professor, Dr. Jayanta Chatterjee

Sai Life Sciences recently hosted Dr. Jayanta Chatterjee, Associate Professor at the Indian Institute of Science (IISc), Bangalore, for two enriching sessions at its campus. The first was the Masterclass Lecture Series, where Dr. Chatterjee addressed a group of scientists at Sai Life Sciences on “Our Adventures in the de novo Design of Helical Macrocyclic […]
Read more

2025.08.13

From vendor to vanguard: Reimagining India’s role in global life sciences

In a recent article published in ET Edge titled, ‘From Vendor to Vanguard: Reimagining India’s Role in Global Life Sciences,’ Krishna Kanumuri, MD & CEO, Sai Life Sciences, highlighted India’s rapidly unfolding transformation from a vendor to an innovation leader in the global life sciences ecosystem.You can read the full article here: From vendor to vanguard: […]
Read more